Table 3. Non-haematological adverse events.
| Non-haematological adverse eventa | Grade 1 n (%) | Grade 2 n (%) | Grade 3 n (%) | All % |
|---|---|---|---|---|
| Stomatitis | 34 (41) | 17 (21) | 7 (9) | 71 |
| Nausea | 31 (38) | 9 (11) | 4 (5) | 54 |
| Diarrhoea | 27 (33) | 8 (10) | 6 (7) | 50 |
| Hand-foot syndrome | 16 (20) | 9 (11) | 9 (11) | 41 |
| Fatigue | 12 (15) | 14 (17) | 5 (6) | 38 |
| Vomiting | 22 (27) | 5 (6) | 0 (0) | 33 |
| Taste alteration | 20 (24) | 6 (7) | 0 (0) | 32 |
| Hypertension | 5 (6) | 9 (11) | 5 (6) | 23 |
| Anorexia | 6 (7) | 12 (15) | 0 (0) | 22 |
| Headache | 7 (9) | 6 (7) | 2 (2) | 18 |
| Yellow skin | 12 (15) | 0 (0) | 0 (0) | 15 |
| Rash/desquamation | 8 (10) | 4 (5) | 0 (0) | 15 |
| Fever | 7 (9) | 4 (5) | 0 (0) | 13 |
| Heartburn | 7 (9) | 4 (5) | 0 (0) | 13 |
| Pain extremity | 7 (9) | 2 (2) | 0 (0) | 13 |
| Esophagitis | 5 (6) | 3 (4) | 1 (1) | 11 |
| Gastric complaints | 7 (9) | 2 (2) | 0 (0) | 11 |
| Myalgia | 8 (10) | 1 (1) | 0 (0) | 11 |
| Periorbital oedema | 9 (11) | 0 (0) | 0 (0) | 11 |
| Dizziness | 7 (9) | 1 (1) | 0 (0) | 10 |
| Epistaxis | 8 (10) | 0 (0) | 0 (0) | 10 |
| Oedema | 3 (4) | 2 (2) | 1 (1) | 7 |
| Pain mouth | 2 (2) | 1 (1) | 1 (1) | 5 |
| Muscle weakness | 0 (0) | 2 (2) | 1 (1) | 4 |
| Cognitive disorder | 0 (0) | 2 (2) | 1 (1) | 4 |
| Hyperthyroidism | 0 (0) | 0 (0) | 1 (1) | 1 |
| Transient ischaemic attack | 0 (0) | 0 (0) | 1 (1) | 1 |
a
Adverse events grade 1 and 2 occurring in at least 10% of patients and all grade 3 events.